List of publications on a keyword: «»


Medicine

Publication date: 14.06.2019
Evaluate the material Average score: 5 (Всего: 1)
Irina V. Dubatova , candidate of medical sciences , associate professor
FSFEI of HE “Rostov State Medical University” of Russian Ministry of Health , Ростовская обл
Andrey V. Antsyborov , graduate student
Mental Health Clinic «Psyche» , Ростовская обл

«The role of impulsivity and impulse control disorders in the formation of addictive disorders»

Download an article

Currently, a lot of researches devoted to the study of the relationship between disorders of impulse control and addictive pathology are published. Attempts to isolate behavioral addictions into a separate group of addictive disorders make it necessary to assess impulsivity and impulse control disorders at different stages of formation, both behavioral and substance use addictions in a new way. This review is based on the results of research and analysis of existing models of addictive disorders, where the dominant position is given to impulsivity and impulse control disorders as predictors of addictive pathology. It contributes to most forms of aberrant management and other disorders included in the current classifications (DSM-V, ICD-10). In our opinion, many existing models of addictive pathology of impulsivity and impulse control disorders is given undeservedly little attention, which in the end leads to an incorrect assessment of substance and behavioral addictions. A model of development of addictive disorders is proposed, where the disorder of impulse control is given a decisive place in the question of «to be or not to be» addictive pathology.

Publication date: 14.06.2019
Evaluate the material Average score: 0 (Всего: 0)
Andrey V. Antsyborov , graduate student
Mental Health Clinic «Psyche» , Ростовская обл
Irina V. Dubatova , candidate of medical sciences , associate professor
FSFEI of HE “Rostov State Medical University” of Russian Ministry of Health , Ростовская обл

«New psychoactive substances: psychiatrist's view»

Download an article

Appearing not long ago, new psychoactive substances (designer drugs), including synthetic cannabinoids, derivatives of cathinone, phenethylamines, new stimulants, synthetic opioids, tryptamine derivatives, phencyclidine, piperazine, the GABA (A/B) receptors agonists, have become a serious problem for consumers and for physicians. Consumers of these substances are attracted primarily by the intensity of psychoactive effects, and the «legal high» declared by the black manufacturers, which indicates that significant difficulties in a laboratory identification of new surfactants. Designer drugs, when ingested, can be influenced on many neurotransmitter pathways/receptors: dopamine, cannabinoid (CB1), GABA (A/B), 5-HT2A, glutamate, and k-opioid receptors (KOR), the imbalance of which leads to the development of polymorphic psychotic disorders.